Orexo’s Q216 results pointed to positive Zubsolv momentum with evidence of net revenue growth, improving margins and encouraging market access developments. Financial discipline contributed to a Q216 SEK12.1m operating profit and a second successive quarter of positive operating cash flow. The new Maryland FFS Medicaid agreement should help boost Zubsolv’s penetration into the public market segment and ongoing expansion in US prescribing rights will be a key growth driver longer t
10 Aug 2016
Margins, Maryland and Mundipharma
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Margins, Maryland and Mundipharma
Orexo’s Q216 results pointed to positive Zubsolv momentum with evidence of net revenue growth, improving margins and encouraging market access developments. Financial discipline contributed to a Q216 SEK12.1m operating profit and a second successive quarter of positive operating cash flow. The new Maryland FFS Medicaid agreement should help boost Zubsolv’s penetration into the public market segment and ongoing expansion in US prescribing rights will be a key growth driver longer t